Investors have a soft spot for dividend stocks. The allure of reliable payouts, strong earnings performance, and steady revenue growth can be enchanting. However, like a dark cloud on a sunny day, dangerous dividend stocks can cast a shadow over your portfolio.
A disastrous dividend stock is akin to a horror movie villain, waiting to unleash havoc on your investment dreams. Nothing can unravel your financial well-being quicker than a malevolent dividend stock lurking in the background, ready to strike.
The worst offenders among dividend stocks put their payouts at risk, slash them, or make them vanish into thin air. After all, what good is a dividend stock if you cannot depend on its consistent payouts?
Dangerous dividend stocks are often lackluster performers, receiving poor analyst ratings, exhibiting a lack of momentum, and delivering disappointing earnings. Be sure to steer clear of these ominous investments.
Approach with Wariness: Ford (F)
Source: JuliusKielaitis / Shutterstock.com
The mention of Ford (NYSE:F) typically conjures images of iconic American vehicles such as the Mustang, Thunderbird, Explorer, and F-150 – a diverse lineup to suit every taste.
However, beneath the surface, Ford stock harbors risks. Sales woes plague Ford’s electric vehicle range, with a 51% drop in year-over-year sales prompting steep price cuts, including an $8,100 reduction in the electric Mustang Mach-E’s price.
While these discounts boosted sales by 81% in February, the sacrifice to profit margins is concerning. Moreover, a recent labor strike with Ford’s United Auto Workers union workers, although resolved, is set to increase Ford’s labor costs.
Despite a dividend yield of nearly 5%, propped up by a supplemental special dividend, Ford faces uncertainty regarding its payout sustainability. The stock’s meager 1% rise over the past year, coupled with a “C” grade in the Portfolio Grader and a “D” in the Dividend Grader, warrant caution.
Exercise Vigilance: Realty Income (O)
Source: Shutterstock
Here lies my former reverence for real estate investment trusts (REITs). These investments, once a staple for dividends due to their unique income distribution structure, have lost their luster in the case of Realty Income (NYSE:O).
Realty Income’s profitability is taking a hit from rising interest rates, escalating the costs of maintaining thousands of properties. The surge in borrowing expenses over the last two years has been particularly detrimental.
Although Realty Income recorded a revenue increase to $1.07 billion in the fourth quarter from $888.7 million a year prior, its income plummeted from $227.3 million to $218.4 million.
Despite a nearly 6% dividend yield, inflated due to the stock’s valuation pressure, Realty Income has tumbled 15% in the last year. With an “F” in the Portfolio Grader and a “D” in the Dividend Grader, exercise caution with this stock.
Exercise Caution: Pfizer (PFE)
Source: photobyphm / Shutterstock.com
The illustrious achievements of Pfizer (NYSE:PFE) during the tumultuous 2020s are commendable. Amid the onset of the Covid-19 pandemic, Pfizer stood at the forefront of vaccine development, undoubtedly saving innumerable lives and ushering the world out of lockdowns.
Nevertheless, even amidst gratitude for Pfizer’s contributions, it remains a treacherous dividend stock. The waning Covid-19 vaccination rates have dented Pfizer’s financial health, casting a shadow on its bottom line.
Assessing the Storm: Financial Turbulence for Key Companies
The Bumpy Ride of Pfizer Inc. (PFE)
The winds of change have not been friendly to Pfizer Inc. (NYSE:PFE). In the recent reckoning, the pharmaceutical titan bore the brunt of a 41% plunge in the fourth quarter compared to a year earlier, as revenue stumbled to $14.2 billion. Meanwhile, income tapered off from $1.14 billion to $593 million in the corresponding period.
This tumultuous performance has sent Pfizer stock plummeting by 29% over the past year. While boasting a tempting dividend yield of 5.9%, the company stands at a pitiful “F” rating in the Portfolio Grader and a dismal “D” grade in the Dividend Grader.
The Disney Dilemma at Walt Disney Co. (DIS)
Walt Disney Co. (NYSE:DIS) finds itself in the eye of a brewing tempest. Since the departure of erstwhile CEO Bob Iger in December 2021, the House of Mouse has been ensnared in a maelstrom of challenges. Bob Chapek, Iger’s successor, known for steering Disney’s iconic parks, was ill-prepared for the gamut of duties, including overseeing ABC, ESPN, and Disney’s movie studio.
The advent of the Covid-19 pandemic piled on grave pressure, further exacerbating Disney’s woes. Despite Iger’s comeback in November 2022, lasting till 2026, Disney continues to grapple with adversity. Strife with Florida Governor Ron DeSantis and intensifying competition in the streaming sphere loom large as formidable hurdles.
The once-buoyant Pixar productions are eclipsed by dwindling returns, while the heralded Marvel franchise appears to have lost its sparkle. Fiscal fortunes portray a fraught landscape, with earnings plateauing at $23.5 billion in the first quarter of fiscal 2024. Furthermore, Disney broke a four-year dividend hiatus in December, proffering a modest payment of 30 cents per share, signaling a rocky road ahead in dividend sustainability.
Despite gripping its investors with bated breath, DIS stock is saddled with a middling “C” classification in the Portfolio Grader and a disheartening “F” rating in the Dividend Grader.
Prescription for Worry: Medical Properties Trust’s (MPW) Financial Health
Medical Properties Trust (NYSE:MPW) treads precarious terrain in the realm of real estate investments. Specializing in health care facilities under triple net leases, the company faces a formidable adversity in the form of a significant tenant default. Steward Health Care System’s truncated rent payments in 2023, owing to liquidity strains, culminated in a substantial debt burden totaling around $50 million by year-end.
Responding to this crisis, Medical Properties Trust unveiled plans in January for a $60 million bridge loan buttressed by Steward assets and secondary liens on the company’s managed care domain. Compelled by the uncertainty surrounding Steward’s fiscal solvency, the company is set to write off approximately $225 million in receivables.
The fallout was stark in the Q4 financials, painting a dismal picture with revenues dwindling from $231.8 million to $78.4 million year-on-year. Prolonged instability has led to a disheartening downturn, with a $663.9 million loss trumping the prior year’s $140.4 million deficit. Amid this tumult, the dividend also bore the brunt, plummeting from 29 cents per share to a modest 15 cents per share.
In the aftermath of this financial turmoil, MPW stock bears the brunt of a 50% descent over the past year. Afflicted with an ignominious “F” status in both the Portfolio Grader and Dividend Grader, caution remains the watchword for investors eying Medical Properties Trust.
Activist Antics: The Case of Icahn Enterprises (IEP)
Icahn Enterprises (NASDAQ:IEP), the investment vehicle steered by activist investor Carl Icahn, finds itself at the crossroads of ambition and adversity. Revered for his bold takeover of Trans World Airlines in 1988, an episode culminating in bankruptcy by 1995 before eventual assimilation by the parent company of American Airlines (NASDAQ:AAL) in 2001, Icahn now sets his sights on a fresh conquest: JetBlue Airways (NASDAQ:JBLU).
The Tale of Two Companies: Icahn Enterprises (IEP) and 3M Company (MMM)
Icahn Enterprises (IEP)
Carl Icahn, known for his savvy investment moves, made waves by securing a 10% stake in Icahn Enterprises (IEP) and landing two seats on the company’s board of directors. However, a dark cloud looms over the airline as it grapples with unprofitability amid the Covid-19 pandemic. A federal judge threw a wrench in its merger plans with Spirit Airlines (NYSE: SAVE).
Last year, IEP stock tumbled by half following a damning report by Hindenburg Research, likening the company’s dividend strategy to a Ponzi scheme and questioning its valuation. The fourth-quarter financials paint a grim picture, with revenue plummeting to $2.64 billion from $3.28 billion, resulting in a net loss of $139 million, or 33 cents per share.
Despite continuing to pay a quarterly dividend of $1 per share, IEP stock faces uncertainties with ratings of “D” in the Portfolio Grader and “F” in the Dividend Grader. The question on everyone’s minds now is how long this dividend can sustain itself amidst the turbulence in the company’s performance.
3M Company (MMM)
Over at 3M Company (MMM), a different narrative unfolds. The company boasts a robust health care unit contributing a quarter of its annual revenue, totaling around $8.2 billion last year. However, investors should brace themselves for a major shift as 3M gears up to spin off this lucrative health care division into a standalone entity named Solventum, set to debut on the New York Stock Exchange under the ticker SOLV.
Although 3M will retain a 19.9% stake in Solventum, allowing it to benefit from the new entity’s success, shareholders might find it disheartening to bid adieu to a significant revenue generator. Fourth-quarter revenue for 3M stock clocked in at $8 billion, marking a slight decline from the previous year.
The impending spinoff raises questions about MMM’s ability to maintain its current dividend yield of nearly 5.9%. While MMM stock has been relatively stable over the past year, it garners “D” ratings in both the Portfolio Grader and the Dividend Grader, hinting at underlying concerns amidst the corporate restructuring.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
